(HLI) Houlihan Lokey - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4415931009

Merger, Acquisition, Restructuring, Valuation, Advisory Services

HLI EPS (Earnings per Share)

EPS (Earnings per Share) of HLI over the last years for every Quarter: "2020-03": 0.89972846843083, "2020-06": 0.69013422436997, "2020-09": 0.70085369409798, "2020-12": 1.7087849265315, "2021-03": 1.4421854408444, "2021-06": 1.2508985922298, "2021-09": 1.646338350876, "2021-12": 2.5444530528018, "2022-03": 0.96607265148573, "2022-06": 1.0283866206003, "2022-09": 0.87005730659026, "2022-12": 0.90427202595313, "2023-03": 0.87596813860441, "2023-06": 0.90278880712466, "2023-09": 0.98767596813787, "2023-12": 1.0429644862071, "2024-03": 1.1837440869007, "2024-06": 1.2983733107935, "2024-09": 1.3672157023223, "2024-12": 1.3859891508268, "2025-03": 1.7622826416894, "2025-06": 1.4158198815469,

HLI Revenue

Revenue of HLI over the last years for every Quarter: 2020-03: 302.694, 2020-06: 211.136, 2020-09: 275.736, 2020-12: 537.876, 2021-03: 500.704, 2021-06: 372.722, 2021-09: 537.272, 2021-12: 888.798, 2022-03: 471.166, 2022-06: 418.644, 2022-09: 489.537, 2022-12: 456.499, 2023-03: 444.767, 2023-06: 415.829, 2023-09: 466.989, 2023-12: 511.13, 2024-03: 520.456, 2024-06: 513.609, 2024-09: 574.957, 2024-12: 634.428, 2025-03: 666.422, 2025-06: 605.349,

Description: HLI Houlihan Lokey

Houlihan Lokey Inc (NYSE:HLI) is a leading investment banking firm that provides a range of financial services, including merger and acquisition advisory, capital market transactions, financial restructuring, and valuation advisory. The companys diversified business model is segmented into three main areas: Corporate Finance, Financial Restructuring, and Financial and Valuation Advisory.

The Corporate Finance segment is a key driver of the companys revenue, providing advisory services on M&A transactions, debt and equity financings, and other corporate finance transactions. The Financial Restructuring segment advises debtors, creditors, and other stakeholders on recapitalization and deleveraging transactions, while the Financial and Valuation Advisory segment provides valuation services, fairness opinions, and dispute resolution services.

From a financial perspective, Houlihan Lokey has demonstrated strong profitability, with a Return on Equity (ROE) of 19.88%. The companys revenue growth is driven by its ability to attract and retain top talent, as well as its diversified business model. Key Performance Indicators (KPIs) to monitor include revenue per employee, deal count, and average deal size. With a market capitalization of $13.8 billion, Houlihan Lokey is a significant player in the investment banking industry.

To evaluate the companys stock performance, its essential to analyze its valuation multiples. The current Price-to-Earnings (P/E) ratio is 33.92, while the forward P/E ratio is 23.58, indicating a potential decline in earnings growth. Investors should also monitor the companys revenue and earnings growth, as well as its ability to maintain a strong balance sheet and generate cash flows.

From a technical analysis perspective, the stock has shown a strong uptrend, with the current price above its 20-day, 50-day, and 200-day moving averages. The Average True Range (ATR) indicates a moderate level of volatility, with a current ATR of 4.23, representing 2.15% of the stocks current price. Investors should monitor the stocks support and resistance levels, with key support levels at $182.1, $179.3, and $175.7.

HLI Stock Overview

Market Cap in USD 13,281m
Sub-Industry Investment Banking & Brokerage
IPO / Inception 2015-08-13

HLI Stock Ratings

Growth Rating 78.2%
Fundamental 85.3%
Dividend Rating 72.6%
Total Return vs S&P 500 8.99%
Analyst Rating 3.44 of 5

HLI Dividends

Dividend Yield 12m 1.60%
Yield on Cost 5y 5.49%
Annual Growth 5y 12.04%
Payout Consistency 100.0%
Payout Ratio 32.5%

HLI Growth Ratios

Growth Correlation 3m 82.6%
Growth Correlation 12m 49.2%
Growth Correlation 5y 91.4%
CAGR 5y 29.27%
CAGR/Max DD 5y 0.80
Sharpe Ratio 12m 1.00
Alpha 10.20
Beta 0.941
Volatility 22.43%
Current Volume 399k
Average Volume 20d 356.4k
Stop Loss 185.4 (-3%)
Signal 1.30

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (408.3m TTM) > 0 and > 6% of Revenue (6% = 148.9m TTM)
FCFTA 0.21 (>2.0%) and ΔFCFTA 9.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 41.65% (prev 10.87%; Δ 30.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.22 (>3.0%) and CFO 781.5m > Net Income 408.3m (YES >=105%, WARN >=100%)
Net Debt (-793.8m) to EBITDA (578.5m) ratio: -1.37 <= 3.0 (WARN <= 3.5)
Current Ratio 21.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (68.9m) change vs 12m ago 0.56% (target <= -2.0% for YES)
Gross Margin 33.89% (prev 36.86%; Δ -2.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 76.81% (prev 68.37%; Δ 8.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' 5.50

(A) 0.29 = (Total Current Assets 1.08b - Total Current Liabilities 51.5m) / Total Assets 3.52b
(B) 0.41 = Retained Earnings (Balance) 1.45b / Total Assets 3.52b
(C) 0.16 = EBIT TTM 530.1m / Avg Total Assets 3.23b
(D) 1.07 = Book Value of Equity 1.43b / Total Liabilities 1.34b
Total Rating: 5.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 85.31

1. Piotroski 5.0pt = 0.0
2. FCF Yield 5.35% = 2.67
3. FCF Margin 29.80% = 7.45
4. Debt/Equity 0.62 = 2.32
5. Debt/Ebitda 2.32 = -0.61
6. ROIC - WACC 10.38% = 12.50
7. RoE 19.47% = 1.62
8. Rev. Trend 86.40% = 4.32
9. Rev. CAGR 7.33% = 0.92
10. EPS Trend 94.57% = 2.36
11. EPS CAGR 17.62% = 1.76

What is the price of HLI shares?

As of August 19, 2025, the stock is trading at USD 191.14 with a total of 398,958 shares traded.
Over the past week, the price has changed by +0.36%, over one month by -2.56%, over three months by +7.22% and over the past year by +26.85%.

Is Houlihan Lokey a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Houlihan Lokey (NYSE:HLI) is currently (August 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 85.31 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HLI is around 215.12 USD . This means that HLI is currently undervalued and has a potential upside of +12.55% (Margin of Safety).

Is HLI a buy, sell or hold?

Houlihan Lokey has received a consensus analysts rating of 3.44. Therefor, it is recommend to hold HLI.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the HLI price?

Issuer Target Up/Down from current
Wallstreet Target Price 202.8 6.1%
Analysts Target Price 175.9 -8%
ValueRay Target Price 240.2 25.6%

Last update: 2025-08-11 02:07

HLI Fundamental Data Overview

Market Cap USD = 13.28b (13.28b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 793.8m USD (last quarter)
P/E Trailing = 31.8533
P/E Forward = 26.5252
P/S = 5.3534
P/B = 6.0984
P/EG = 6.54
Beta = 0.867
Revenue TTM = 2.48b USD
EBIT TTM = 530.1m USD
EBITDA TTM = 578.5m USD
Long Term Debt = 1.29b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 51.5m USD (from totalCurrentLiabilities, last quarter)
Debt = 1.34b USD (Calculated: Short Term 51.5m + Long Term 1.29b)
Net Debt = -793.8m USD (from netDebt column, last quarter)
Enterprise Value = 13.83b USD (13.28b + Debt 1.34b - CCE 793.8m)
Interest Coverage Ratio = unknown (Ebit TTM 530.1m / Interest Expense TTM 0.0)
FCF Yield = 5.35% (FCF TTM 739.5m / Enterprise Value 13.83b)
FCF Margin = 29.80% (FCF TTM 739.5m / Revenue TTM 2.48b)
Net Margin = 16.46% (Net Income TTM 408.3m / Revenue TTM 2.48b)
Gross Margin = 33.89% ((Revenue TTM 2.48b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Tobins Q-Ratio = 9.64 (Enterprise Value 13.83b / Book Value Of Equity 1.43b)
Interest Expense / Debt = 0.35% (Interest Expense 4.68m / Debt 1.34b)
Taxrate = 24.77% (from yearly Income Tax Expense: 131.6m / 531.3m)
NOPAT = 398.8m (EBIT 530.1m * (1 - 24.77%))
Current Ratio = 21.07 (Total Current Assets 1.08b / Total Current Liabilities 51.5m)
Debt / Equity = 0.62 (Debt 1.34b / last Quarter total Stockholder Equity 2.18b)
Debt / EBITDA = 2.32 (Net Debt -793.8m / EBITDA 578.5m)
Debt / FCF = 1.81 (Debt 1.34b / FCF TTM 739.5m)
Total Stockholder Equity = 2.10b (last 4 quarters mean)
RoA = 11.61% (Net Income 408.3m, Total Assets 3.52b )
RoE = 19.47% (Net Income TTM 408.3m / Total Stockholder Equity 2.10b)
RoCE = 15.66% (Ebit 530.1m / (Equity 2.10b + L.T.Debt 1.29b))
RoIC = 19.01% (NOPAT 398.8m / Invested Capital 2.10b)
WACC = 8.64% (E(13.28b)/V(14.62b) * Re(9.48%)) + (D(1.34b)/V(14.62b) * Rd(0.35%) * (1-Tc(0.25)))
Shares Correlation 5-Years: 20.0 | Cagr: 0.18%
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.50% ; FCFE base≈577.9m ; Y1≈624.8m ; Y5≈774.6m
Fair Price DCF = 193.3 (DCF Value 10.51b / Shares Outstanding 54.4m; 5y FCF grow 9.16% → 3.0% )
Revenue Correlation: 86.40 | Revenue CAGR: 7.33%
Revenue Growth Correlation: 73.22%
EPS Correlation: 94.57 | EPS CAGR: 17.62%
EPS Growth Correlation: 24.13%

Additional Sources for HLI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle